Does the media refer more to TNGX or CRVS?

In the previous week, Tango Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for Tango Therapeutics and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Tango Therapeutics' score of 0.93 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings & valuation, CRVS or EWTX?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.66 N/A

Is CRVS or EWTX more profitable?

Edgewise Therapeutics' return on equity of -32.55% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -38.92% -35.75% Edgewise Therapeutics N/A -32.55% -31.04%

Does the media prefer CRVS or EWTX?

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Edgewise Therapeutics' score of 1.50 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to CRVS or CPRX?

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Catalyst Pharmaceuticals' score of 0.93 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, CRVS or DNLI?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A Denali Therapeutics N/A N/A -$512.54M -$2.88 N/A

Is CRVS or DNLI more profitable?

Corvus Pharmaceuticals' return on equity of -38.92% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -38.92% -35.75% Denali Therapeutics N/A -52.20% -43.86%

Does the media prefer CRVS or DNLI?

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Denali Therapeutics' score of 0.94 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACAD or CRVS?

In the previous week, ACADIA Pharmaceuticals had 10 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 12 mentions for ACADIA Pharmaceuticals and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat ACADIA Pharmaceuticals' score of 0.93 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Corvus Pharmaceuticals (CRVS) Competitors

$13.98 +0.49 (+3.66%)

As of 10:53 AM Eastern

Compare

CRVS vs. TNGX, EWTX, CPRX, DNLI, and ACAD

Should you buy Corvus Pharmaceuticals stock or one of its competitors? MarketBeat compares Corvus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corvus Pharmaceuticals include Tango Therapeutics (TNGX), Edgewise Therapeutics (EWTX), Catalyst Pharmaceuticals (CPRX), Denali Therapeutics (DNLI), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.

How does Corvus Pharmaceuticals compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Corvus Pharmaceuticals has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	73.53	-$101.59M	-$0.83	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Tango Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Tango Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for Tango Therapeutics and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Tango Therapeutics' score of 0.93 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Corvus Pharmaceuticals has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Corvus Pharmaceuticals' return on equity of -38.92% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Tango Therapeutics currently has a consensus target price of $41.50, indicating a potential upside of 30.88%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 138.37%. Given Corvus Pharmaceuticals' higher probable upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Corvus Pharmaceuticals beats Tango Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Edgewise Therapeutics?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Corvus Pharmaceuticals has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Edgewise Therapeutics' score of 1.50 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Edgewise Therapeutics' return on equity of -32.55% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Corvus Pharmaceuticals currently has a consensus target price of $33.33, suggesting a potential upside of 138.37%. Edgewise Therapeutics has a consensus target price of $47.30, suggesting a potential upside of 15.52%. Given Corvus Pharmaceuticals' higher possible upside, equities analysts plainly believe Corvus Pharmaceuticals is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Corvus Pharmaceuticals and Edgewise Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Catalyst Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Catalyst Pharmaceuticals' score of 0.93 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals presently has a consensus price target of $33.33, indicating a potential upside of 138.37%. Catalyst Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 1.76%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Corvus Pharmaceuticals is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Corvus Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Corvus Pharmaceuticals' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Catalyst Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Catalyst Pharmaceuticals	$588.99M	6.54	$214.33M	$1.74	18.07

Summary

Catalyst Pharmaceuticals beats Corvus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Denali Therapeutics?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Denali Therapeutics	N/A	N/A	-$512.54M	-$2.88	N/A

Corvus Pharmaceuticals' return on equity of -38.92% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Denali Therapeutics	N/A	-52.20%	-43.86%

Corvus Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Denali Therapeutics' score of 0.94 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals currently has a consensus price target of $33.33, indicating a potential upside of 138.37%. Denali Therapeutics has a consensus price target of $34.25, indicating a potential upside of 33.14%. Given Corvus Pharmaceuticals' higher probable upside, equities analysts plainly believe Corvus Pharmaceuticals is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

Summary

Corvus Pharmaceuticals beats Denali Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals currently has a consensus price target of $31.88, indicating a potential upside of 24.75%. Corvus Pharmaceuticals has a consensus price target of $33.33, indicating a potential upside of 138.37%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

ACADIA Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 10 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 12 mentions for ACADIA Pharmaceuticals and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat ACADIA Pharmaceuticals' score of 0.93 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ACADIA Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.10B	4.00	$391M	$2.20	11.62
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Corvus Pharmaceuticals' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Summary

ACADIA Pharmaceuticals beats Corvus Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Get Corvus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVS vs. The Competition

Export

Metric	Corvus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.17B	$3.63B	$6.84B	$12.34B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-26.78	21.47	25.87	24.19
Price / Sales	N/A	340.70	553.99	100.49
Price / Cash	106.43	62.10	29.09	36.93
Price / Book	19.16	8.38	10.79	6.42
Net Income	-$15.28M	$23.92M	$3.58B	$337.00M
7 Day Performance	11.34%	2.52%	2.49%	0.94%
1 Month Performance	12.68%	0.15%	0.21%	-0.66%
1 Year Performance	259.49%	66.07%	35.20%	27.96%

Corvus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVS Corvus Pharmaceuticals	3.02 of 5 stars	$13.98 +3.7%	$33.33 +138.4%	+246.0%	$1.17B	N/A	N/A	30	Positive News Gap Up
TNGX Tango Therapeutics	2.7863 of 5 stars	$28.39 -0.4%	$38.42 +35.3%	+528.1%	$4.12B	$62.38M	N/A	90	Analyst Forecast
EWTX Edgewise Therapeutics	3.6167 of 5 stars	$38.83 +6.4%	$47.30 +21.8%	+214.8%	$3.93B	N/A	N/A	60	Positive News
CPRX Catalyst Pharmaceuticals	3.4918 of 5 stars	$31.40 +0.1%	$32.00 +1.9%	+44.6%	$3.84B	$588.99M	18.05	80
DNLI Denali Therapeutics	3.0782 of 5 stars	$24.77 +3.0%	$34.25 +38.3%	+81.3%	$3.82B	$330.53M	N/A	430

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVS) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. TNGX, EWTX, CPRX, DNLI, and ACAD

How does Corvus Pharmaceuticals compare to Tango Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Catalyst Pharmaceuticals?

Summary

How does Corvus Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. TNGX, EWTX, CPRX, DNLI, and ACAD

How does Corvus Pharmaceuticals compare to Tango Therapeutics?

Which has higher valuation & earnings, TNGX or CRVS?

Which has more volatility and risk, TNGX or CRVS?

Do institutionals & insiders believe in TNGX or CRVS?

Does the media refer more to TNGX or CRVS?

Is TNGX or CRVS more profitable?

Do analysts recommend TNGX or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Edgewise Therapeutics?

Which has higher earnings & valuation, CRVS or EWTX?

Which has more risk & volatility, CRVS or EWTX?

Do institutionals & insiders hold more shares of CRVS or EWTX?

Does the media prefer CRVS or EWTX?

Is CRVS or EWTX more profitable?

Do analysts rate CRVS or EWTX?

Summary

How does Corvus Pharmaceuticals compare to Catalyst Pharmaceuticals?

Does the media refer more to CRVS or CPRX?

Do analysts prefer CRVS or CPRX?

Do insiders & institutionals believe in CRVS or CPRX?

Which has more risk and volatility, CRVS or CPRX?

Is CRVS or CPRX more profitable?

Which has better valuation & earnings, CRVS or CPRX?

Summary

How does Corvus Pharmaceuticals compare to Denali Therapeutics?

Do institutionals & insiders believe in CRVS or DNLI?

Which has stronger earnings and valuation, CRVS or DNLI?

Is CRVS or DNLI more profitable?

Which has more risk and volatility, CRVS or DNLI?

Does the media prefer CRVS or DNLI?

Do analysts recommend CRVS or DNLI?

Summary

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

Do insiders & institutionals have more ownership in ACAD or CRVS?

Do analysts prefer ACAD or CRVS?

Which has more risk and volatility, ACAD or CRVS?

Does the media favor ACAD or CRVS?

Which has higher valuation & earnings, ACAD or CRVS?

Is ACAD or CRVS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools